Logo Logo
Help
Contact
Switch Language to German
Nitz, Ulrike; Gluz, Oleg; Clemens, Michael; Malter, Wolfram; Reimer, Toralf; Nuding, Benno; Aktas, Bahriye; Stefek, Andrea; Pollmanns, Anke; Lorenz-Salehi, Fatemeh; Uleer, Christoph; Krabisch, Petra; Kümmel, Sherko; Liedtke, Cornelia; Shak, Steven; Wuerstlein, Rachel; Christgen, Matthias; Kates, Ronald E.; Kreipe, Hans H.; Harbeck, Nadia; Ackermann, S.; Aktas, B.; Augustin, D.; Baake, G.; Baumann, K.; Berger, R.; Bettscheider, J.; Bischoff, J.; Clemens, M.; Deryal, M.; Dubbers, H.; Duchting, D.; Dunnebacke, J.; Fett, W.; Fietz, T.; Fischer, H.; Forner, M.; Forstbauer, H.; Freese, K.; Geberth, M.; Glados, M.; Gnauert, K.; Goette, O.; Gohring, U.; Goppinger, A.; Grafe, A.; Hackenberg, R.; Hackmann, J.; Hellriegel, M.; Heyl, V.; Hoestermann, C.; Hoffmann, G.; Hofmann, M.; Hucke, J.; Jackisch, C.; Jungberg, P.; Just, M.; Kahl, C.; Klare, P.; Kogel, M.; Kohls, A.; Amrawy, B. Konigs-El; Konnecke, P.; Krabisch, P.; Kraudelt, S.; Kremers, S.; Kummel, S.; Kurbacher, C.; Kusche, J.; Liedtke, B.; Liedtke, C.; Link, H.; Lorenz, R.; Salehi, F. Lorenz; Lubbe, K.; Malter, W.; Melekian, B.; Mobus, V.; Montenarh, M.; Müller, V.; Mundhenke, C.; Niederle, N.; Nitz, U.; Noesselt, T.; Oberhoff, C.; Paas, L.; Paepke, S.; Pollmanns, A.; Reichert, D.; Reimer, T.; Romann, D.; Ruhland, T.; Runde, V.; Salem, M.; Schlosser, A.; Schneider, A.; Schrader, I.; Schulz, H.; Schumacher, C.; Schwickerath, J.; Soling, U.; Stauder, H.; Stefek, A.; Steinmetz, T.; Stickeler, E.; Terhaag, J.; Thomssen, C.; Tome, O.; Uleer, C.; Warm, M.; Wachsmann, G.; Wacker, J.; Wiebringhaus, H.; Wiest, W.; Wolfgarten, M.; Nitz, U.; Christgen, H.; Kreipe, H.; Buehne, C.; Gluz, O.; Hansen, K.; Hofmann, D.; Kates, R.; Mangold, M.; Mathissen, M.; Raeth, P.; Renner, I.; Reiser, I.; Schumacher, J.; Staedele, M.; Walter-Kirst, R. (2019): West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. In: Journal of Clinical Oncology, Vol. 37, No. 10
Full text not available from 'Open Access LMU'.

Abstract

PURPOSE The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment of human epidermal growth factor receptor 2-negative early breast cancer (EBC). PATIENTS AND METHODS Patients with pT1 to pT4c, all pN+, and pN0/high-risk EBC were eligible. High-risk pN0 was defined by one or more of the following: pT greater than 2, grade 2 to 3, high urokinase-type plasminogen activator/plasminogen activator inhibitor-1, hormone receptor (HR) negativity, and less than 35 years of age. After an early amendment, all HR-positive tumors underwent recurrence score (RS) testing, with chemotherapy omission recommended in RS less than or equal to 11 pN0 to pN1 disease. Patients were randomly assigned to four cycles of epirubicin (E)(90)/cyclophoshamide (C)(600) followed by four cycles of docetaxel (T)(100) or six cycles of T75C600 (administered once every 3 weeks). The primary end point was disease-free survival (DFS);secondary end points were overall survival (OS) and safety. The protocol specified P = .05 for a noninferiority margin of 4.4% for all patients combined. RESULT Of the 3,198 registered patients, 348 (RS <= 11) omitted chemotherapy, and 401 were not randomly assigned. The intention-to-treat population included 2,449 patients (1,227 EC-T v 1,222 TC: postmenopausal, 62.2% v60.8%;pNO, 58.2% v59.5%;pT1, 57.6% v52.3%;HR positive, 81.4% v82.2%;RS greater than 25 [in H.R-positive patients], 26.2% v 27.5%). Within the safety population (1,167 v 1,178 patients), 87.5% v 93.0% completed therapy. After a 60-month median follow-up, 5-year outcomes were similar in the EC-T and TC arms (DFS, 89.6% [95% CI, 87.9% to 91.5%] v89.9% [95% CI, 88.1% to 91.8%];OS, 94.5% [95% CI, 93.1% to 95.9%] v94.7% [95% CI, 93.3% to 96.1%]). The DFS difference was within the noninferiority margin of the original trial design. Five treatment-related deaths were reported for TC (one for EC-T), despite a trend toward more-severe adverse events in the latter. Interaction analysis revealed no predictive trends with respect to key factors, including triple-negative, luminal A/B-like, pN, age, and RS status. CONCLUSION In the West German Study Group PlanB trial, 5-year outcomes for TC and EC-T were equally excellent. Six cycles of TC is an effective/safe option in human epidermal growth factor receptor 2-negative EBC with pN0 high genomic risk or pN1 EBC with genomically intermediate- to high-risk disease. (C) 2019 by American Society of Clinical Oncology

Search for authors
Export